Sanofi CEO Belen Garijo Says Beyond 2030, Expect Total Revenues To Be Impacted Only Moderately By Dupixent's Loss Of Exclusivity
-Analyst Call.
Share
Why It Matters
Sanofi's CEO says a popular drug called Dupixent will lose its special protection after 2030. The company thinks this will only hurt their money a little bit, so they are planning ahead.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.